Table 5.
Metabolite discovery among normal weight women (n=630), and an evaluation of association with C-reactive protein1,2,3
| Association with EDIP score | Association with CRP | ||||
|---|---|---|---|---|---|
| Metabolite | HMDB # | Beta estimate (95%CI) | FDR-adjusted P-value | Beta estimate (95%CI) | FDR-adjusted P-value |
| 5-acetylamino-6-amino-3-methyluracil | HMDB0004400 | −1.07 (−1.48, −0.67) | 9.72 E-05 | −0.003 (−0.07, 0.07) | 0.932 |
| Trigonelline | HMDB0001847 | −0.86 (−1.24, −0.48) | 0.002 | −0.01 (−0.08, 0.05) | 0.736 |
| 1,7-dimethyluric acid | HMDB0011103 | −0.86 (−1.28, −0.43) | 0.008 | 0.05 (−0.02, 0.12) | 0.392 |
| Caffeine | HMDB0001847 | −0.89 (−1.33, −0.45) | 0.008 | 0.05 (−0.02, 0.13) | 0.372 |
1
All values are beta estimates obtained from multivariable-adjusted linear regression modeling 5-SD increments in EDIP or 5-unit increments in CRP as the main predictor of interest and metabolite as the main response variable of interest.
2
Models were adjusted for body mass index (continuous) age, physical activity, educational level, race/ethnicity, aspirin/NSAIDs use, smoking status, WHI Hormone Therapy trial arm, CHD case-control status.
3
Statistical significance was defined as false-discovery rate adjusted p<0.05.